1. Home
  2. BHF vs ABCL Comparison

BHF vs ABCL Comparison

Compare BHF & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brighthouse Financial Inc.

BHF

Brighthouse Financial Inc.

HOLD

Current Price

$52.27

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.32

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHF
ABCL
Founded
2016
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.5B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
BHF
ABCL
Price
$52.27
$11.32
Analyst Decision
Hold
Strong Buy
Analyst Count
8
5
Target Price
$57.71
$8.40
AVG Volume (30 Days)
949.9K
8.7M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
23.06
10.91
EPS
2.84
N/A
Revenue
$6,766,000,000.00
$75,128,000.00
Revenue This Year
$27.10
N/A
Revenue Next Year
$1.09
$21.85
P/E Ratio
$18.74
N/A
Revenue Growth
43.23
160.56
52 Week Low
$43.25
$2.75
52 Week High
$66.80
$12.15

Technical Indicators

Market Signals
Indicator
BHF
ABCL
Relative Strength Index (RSI) 17.63 73.83
Support Level N/A $3.38
Resistance Level $64.01 N/A
Average True Range (ATR) 1.72 0.87
MACD -0.86 0.35
Stochastic Oscillator 3.86 87.21

Price Performance

Historical Comparison
BHF
ABCL

About BHF Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: